Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Hormone Research in Paediatrics|March 19, 2019
Hypothalamic Obesity: Prologue and PromiseM Jennifer Abuzzahab, Christian L Roth, Ashley H Shoemaker
Pediatric Emergency Care|January 31, 2023
Intravenous Fluid Bolus Volume and Resolution of Acute Kidney Injury in Children With Diabetic KetoacidosisKelly R Bergmann, Morgan Boes, Heidi Vander Velden, et al.
International Journal of Pediatric Endocrinology|December 9, 2020
Outcomes in children treated with growth hormone for Prader-Willi syndrome: data from the ANSWER Program® and NordiNet® International Outcome StudyMoris Angulo, M Jennifer Abuzzahab, Alberto Pietropoli, et al.
Diabetes, Obesity & Metabolism|March 7, 2017
A randomized, placebo-controlled trial of beloranib for the treatment of hypothalamic injury-associated obesityAshley Shoemaker, Joseph Proietto, M Jennifer Abuzzahab, et al.
Diabetes, Obesity & Metabolism|March 2, 2021
MRI measures of hypothalamic injury are associated with glucagon-like peptide-1 receptor agonist treatment response in people with hypothalamic obesityFrancisco A Perez, Clinton Elfers, Jack A Yanovski, et al.
Pediatric Emergency Care|July 19, 2018
Resuscitation With Ringer's Lactate Compared With Normal Saline for Pediatric Diabetic KetoacidosisKelly R Bergmann, M Jennifer Abuzzahab, Jeffrey Nowak, et al.
European Journal of Endocrinology|February 19, 2026
Somapacitan in children with idiopathic short stature: a randomised controlled phase 3 studyM Jennifer Abuzzahab, Andrew Dauber, Michael Højby, et al.
The Lancet. Diabetes & Endocrinology|May 2, 2024
Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trialChristian L Roth, Cecilia Scimia, Ashley H Shoemaker, et al.
BMJ Open|June 5, 2024
Multicentre, retrospective cohort study protocol to identify racial and ethnic differences in acute kidney injuries in children and adolescents with diabetic ketoacidosisKelly R Bergmann, Petter Bjornstad, M Jennifer Abuzzahab, et al.
Diabetes, Obesity & Metabolism|October 7, 2020
A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesityChristian L Roth, Francisco A Perez, Kathryn B Whitlock, et al.
Pageof 3